Literature DB >> 16919955

Induced dystrophin exon skipping in human muscle explants.

G McClorey1, A M Fall, H M Moulton, P L Iversen, J E Rasko, M Ryan, S Fletcher, S D Wilton.   

Abstract

Antisense oligonucleotide (AO) manipulation of pre-mRNA splicing of the dystrophin gene is showing promise in overcoming Duchenne muscular dystrophy (DMD)-causing mutations. To date, this approach has been limited to studies using animal models or cultured human muscle cells, and evidence that AOs can induce exon skipping in human muscle has yet to be shown. In this study, we used different AO analogues to induce exon skipping in muscle explants derived from normal and DMD human tissue. We propose that inducing exon skipping in human muscle explants is closer to in vivo conditions than cells in monolayer cultures, and may minimize the numbers of participants in Phase I clinical studies to demonstrate proof of principle of exon skipping in human muscle.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919955     DOI: 10.1016/j.nmd.2006.05.017

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  19 in total

1.  Dystrophin isoform induction in vivo by antisense-mediated alternative splicing.

Authors:  Sue Fletcher; Abbie M Adams; Russell D Johnsen; Kane Greer; Hong M Moulton; Steve D Wilton
Journal:  Mol Ther       Date:  2010-03-23       Impact factor: 11.454

Review 2.  Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update.

Authors:  Omar Sheikh; Toshifumi Yokota
Journal:  Arch Toxicol       Date:  2021-11-19       Impact factor: 5.153

3.  Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers.

Authors:  Eugene J Wyatt; Alexis R Demonbreun; Ellis Y Kim; Megan J Puckelwartz; Andy H Vo; Lisa M Dellefave-Castillo; Quan Q Gao; Mariz Vainzof; Rita C M Pavanello; Mayana Zatz; Elizabeth M McNally
Journal:  JCI Insight       Date:  2018-05-03

4.  Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene.

Authors:  Linda J Popplewell; Capucine Trollet; George Dickson; Ian R Graham
Journal:  Mol Ther       Date:  2009-01-13       Impact factor: 11.454

Review 5.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

6.  Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient.

Authors:  Takashi Saito; Akinori Nakamura; Yoshitsugu Aoki; Toshifumi Yokota; Takashi Okada; Makiko Osawa; Shin'ichi Takeda
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

7.  Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity.

Authors:  Verena Krähling; David A Stein; Martin Spiegel; Friedemann Weber; Elke Mühlberger
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

Review 8.  Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.

Authors:  Annemieke Aartsma-Rus; Gert-Jan B van Ommen
Journal:  RNA       Date:  2007-08-07       Impact factor: 4.942

Review 9.  Progress toward therapy with antisense-mediated splicing modulation.

Authors:  Liutao Du; Richard A Gatti
Journal:  Curr Opin Mol Ther       Date:  2009-04

Review 10.  Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies.

Authors:  Dunhui Li; Craig Stewart McIntosh; Frank Louis Mastaglia; Steve Donald Wilton; May Thandar Aung-Htut
Journal:  Transl Neurodegener       Date:  2021-05-20       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.